TARO — Taro Pharmaceutical Industries Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareBalancedMid Cap
- $1.62bn
- $735.77m
- $629.18m
Annual cashflow statement for Taro Pharmaceutical Industries, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 6-K |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 245 | -401 | 58.3 | 25.4 | 53.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -12.6 | 0.584 | 12.9 | 10.6 | -7.65 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 10.6 | 461 | -279 | -53.2 | 28.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 272 | 45.8 | -159 | 31.8 | 125 |
| Capital Expenditures | -28.4 | -17.2 | -111 | -19.8 | -54.2 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -270 | 84.9 | -59.3 | -106 | 139 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -298 | 67.7 | -171 | -126 | 84.3 |
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | -27 | -24.2 | -24.9 | 0 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -54.1 | 91.8 | -354 | -96.6 | 208 |